EyePoint Pharmaceuticals (EYPT) Misses Q3 EPS by 8c
Tweet
Share
E-mailGet Alerts EYPT Hot Sheet
Join SI Premium – FREE
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.85), $0.08 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $966 thousand versus the consensus estimate of $3.46 million.
For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
- Barclays Starts Darling Ingredients (DAR) at Equalweight
- JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
